-
公开(公告)号：EP3186279B1
公开(公告)日：2024-01-10
申请号：EP15753906.5
申请日：2015-07-31
-
公开(公告)号：EP3331915B1
公开(公告)日：2021-02-17
申请号：EP16757165.2
申请日：2016-08-05
IPC分类号： C07K16/28 , G01N33/574 , A61K39/395 , A61P35/02
-
公开(公告)号：EP2552964B1
公开(公告)日：2019-10-02
申请号：EP11711591.5
申请日：2011-04-01
发明人： KUFER, Peter , KISCHEL, Roman , RAU, Doris , HOFFMANN, Patrick , LUTTERBUESE, Ralf , KLINGER, Matthias , STEIGER, Carola , FLUHR, Petra , HAUSMANN, Susanne , MANGOLD, Susanne , SCHALLER, Evelyne , RAUM, Tobias
IPC分类号： C07K16/28 , C07K16/30 , C07K16/40 , A61K39/395
-
公开(公告)号：EP2780375B1
公开(公告)日：2019-09-11
申请号：EP12805432.7
申请日：2012-11-15
发明人： KUFER, Peter , RAUM, Tobias , HOFFMANN, Patrick , KISCHEL, Roman , LUTTERBUESE, Ralf , RAU, Doris , ADAM, Paul , BORGES, Eric , HEBEIS, Barbara , HIPP, Susanne
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , A61P37/00
-
公开(公告)号：EP2914289B1
公开(公告)日：2019-05-22
申请号：EP13798260.9
申请日：2013-10-31
发明人： RAST, Markus , STEINHILBER, Wolfram , DE MUYNCK, Christian , BECKER, Gerhard , PEDERSEN, Pernille Dybendal , URBIG, Thomas , BOEHM, Thomas
IPC分类号： A61K39/395 , A61K47/18 , A61K47/26 , A61K9/19
-
公开(公告)号：EP3149480B1
公开(公告)日：2018-12-26
申请号：EP15727072.9
申请日：2015-05-20
发明人： ZUGMAIER, Gerhard , KUFER, Peter , ALEKAR, Shilpa
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , A61K35/17 , A61K38/1774 , A61K2035/124 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/622 , G01N33/5091 , G01N2333/70503 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
公开(公告)号：EP3411404A1
公开(公告)日：2018-12-12
申请号：EP17703714.0
申请日：2017-02-02
发明人： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
CPC分类号： C07K16/3069 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/622 , C07K2317/64
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：EP3411402A1
公开(公告)日：2018-12-12
申请号：EP17703376.8
申请日：2017-02-02
发明人： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2317/64 , C07K2317/94 , C07K2319/00
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：EP3330293A1
公开(公告)日：2018-06-06
申请号：EP17206868.6
申请日：2009-11-06
发明人： ZUGMAIER, Gerhard
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2809 , C07K16/3061 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
-
10.发明授权PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY SPECIFIC FOR EPCAM 有权包含对EPCAM特异的双特异性抗体的药物组合物
公开(公告)号：EP1629013B1
公开(公告)日：2018-01-24
申请号：EP04734816.4
申请日：2004-05-26
发明人： KUFER, Peter , BERRY, Meera , OFFNER, Sonja , BRISCHWEIN, Klaus , WOLF, Andreas , RAUM, Tobias , KOHLEISEN, Birgit , LENKKERI-SCHÜTZ, Ulla , BÄUERLE, Patrick
IPC分类号： C07K16/30 , C07K16/28 , A61K39/395
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
-
-
-
-
-
-
-
-
-
搜索结果
123 条记录 (耗时 0.04 秒)
